TY - JOUR T1 - IP-10 decreases during antituberculous treatment in children with active tuberculosis JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2020.5302 VL - 56 IS - suppl 64 SP - 5302 AU - Agnieszka Strzelak AU - Anna Komorowska-Piotrowska AU - Agnieszka Borowa AU - Maria Krasińska AU - Wojciech Feleszko AU - Marek Kulus Y1 - 2020/09/07 UR - http://erj.ersjournals.com/content/56/suppl_64/5302.abstract N2 - Background: Biomarkers for treatment monitoring in childhood tuberculosis (TB) are needed. Interferon-inducible protein-10 (IP-10) has been shown to decrease upon anti-TB treatment in adults, but not in children.Objective: To investigate changes in IP-10 level during anti-TB treatment in children in a low TB incidence setting and to compare it with IFN-γ.Methods: IP-10 and IFN-γ responses were determined in Quantiferon-TB Gold supernatants in 25 children with active TB, 29 with latent TB infection (LTBI), and 6 TB contacts before and after 2 months of anti-TB treatment.Results: Plasma IP-10 and IFN-γ levels significantly differentiated Mycobacterium tuberculosis-infected children (active TB + LTBI) from uninfected TB contacts at the treatment onset (p=0.003 and p=0.008, respectively), but not active TB from LTBI. A significant decrease in IP-10 but not IFN-γ expression was noticed upon treatment (p=0.0013). Notably, while IP-10 significantly declined in ATB group, no significant decrease was detected in children with LTBI and TB contacts. After 2 months of treatment there was still a significant difference between infected and uninfected children in IP-10 (p=0.008), but not IFN-γ responses. Moreover, on follow-up examination IP-10 differentiated between ATB and LTBI (p=0.015) and between ATB and TB-contacts (p=0.0007).Conclusions: Our results demonstrate that IP-10 declines during anti-TB chemotherapy in childhood active TB and suggest it has the potential to become a biomarker for treatment monitoring in children.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 5302.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -